Jasmine Zain, MD, PhD, discusses CAR T-cell therapy in T-cell lymphoma.

Challenges in CAR T-Cell Therapies in T-Cell Lymphomas

Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.

Videos

Challenges With CAR T-Cell Therapies in T-Cell Lymphomas

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

At the Center for the Lymphoid Malignancies, researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas. The two agents approved in this space, vorinostat and romidepsin, both have response rates close to 30%. Zain says the goal is to improve on these response rates in the relapsed setting and even move them to the upfront setting.

Activity remains to be seen in a phase I trial looking at romidepsin and 5-azacytidine. In another trial, activity is just being observed with pralatrexate and romidepsin. Both trials are open and enrolling.

Jasmine Zain, MD

Articles

Challenges With CAR T-Cell Therapies in T-Cell Lymphomas

Dr. Zain Discusses Ongoing Trials in T-Cell Lymphomas